Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

AToME group aims

  • Continue development of a platform to serve as a trial simulation tool to in the planning and design of clinical trials.
  • Use a recently funded Bill and Melinda Gates Foundation (BMGF) grant to offer analytical support to GMS countries to best inform their NSTs (national strategic plans) targeting elimination. This involves several stages of software development and integration with existing surveillance data collection tools.
  • Model triple artemisinin combination therapies (TACTs). The group is part of a large team UKAid funded DeTACT project trialling two different TACTs in 12 countries. We will investigate which combination of drugs are expected to slow down the spread of ACT resistance in SE emergence in Africa. A strong health economics component will aim to build a business case for first line therapy replacement.
  • We continue to assess the cost effectiveness of different malaria intervention packages building on an extensive costing work of different intervention as part of the BMGF-funded Malaria Modelling Consortium cost effectiveness work package.
  • Model cost-effective unified treatment strategies for multiple malaria species.
In this section